Abstract:Non‐alcoholic fatty liver disease (NAFLD) comprises a spectrum of liver damage directly related to diabetes, metabolic syndrome, and obesity. The (Pro)renin receptor (PRR) in the liver recently has been shown to play an important role in hepatic steatosis. In this study, we test our hypothesis that PRR antagonist, PRO20, reduces hepatic steatosis and fibrosis. Wild‐type mice in C57Bl/6J background (n=9‐10/group) were fed with either HFD (60% calories from fat) or normal fat chow (NFD, 10% calories from fat) with matching calories for 6 weeks. Methionine choline deficient (MCD) diet was used to study fibrosis development in C57BL/6J mice for 8 weeks. Two weeks following respective diet modifications, mice were implanted with a subcutaneous osmotic pump (4 or 6 week release model) containing either PRO20 (700ug/kg/d) or saline. Liver tissues were processed for Oil Red O (ORO), H&E, and Masson’s trichrome histology staining for lipid and collagen accumulation. The presence of lipids, indicative of steatosis, was quantified using ImageJ/FIJI software and presented as % of ORO staining to the total area. We found that 6 weeks of HFD (15.90 ± 1.49 %) induced a significant elevation on liver ORO staining compared with the liver from mice fed with NFD (3.60 ± 1.61 %, p<0.0001). More importantly, PRO20 treatment (9.91 ± 1.46 %; p = 0.001) significantly reduced the ORO staining in mice treated with HFD. Hepatic triglyceride concentrations were quantified with colorimetric assay and shown to be significantly lowered in PRO20 treated mice (2.110 ± 0.6175) compared with scramble peptide treated (6.470 ± 0.3553, p<0.0001) mice under HFD. Collagen area was also found to be reduced in MCD PRO20 (4.970 ± 0.9096 %) treated mice compared with the control mice (8.901 ± 0.2782, p = 0.0033). Moreover, PRO20 treatment (258 ± 53.12 U/L) decreased liver ALT levels in MCD‐fed PRO20 mice compared with the control mice (682 ± 116.4 U/L). De novo lipogenesis genes thought to contribute to the development and progression of NAFLD were evaluated by real‐time PCR and presented as fold‐change expression normalized to β‐actin. The glycerol‐3‐phosphate acetyltransferase 3 (GPAT3) (1.835 ± 0.1798, p = 0.0183) expression was found to be downregulated in the livers of HFD PRO20 treated mice. Our findings indicate that PRO20 reduces HFD‐induced hepatic steatosis and MCD‐induced liver fibrosis and liver dysfunction. We conclude that PRR antagonism using PRO20 might be an effective therapeutic approach for treatment of NAFLD.

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice

FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid

Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis

Fluorofenidone Ameliorates Cholestasis and Fibrosis by Inhibiting Hepatic Erk/-Egr-1 Signaling and Tgfβ1/Smad Pathway in Mice.

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis

Ursodeoxycholyl Lysophosphatidylethanolamide Attenuates Hepatofibrogenesis by Impairment of TGF‐β1/Smad2/3 Signalling

Oxy210, a novel inhibitor of hedgehog and TGF‐β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice

Ursodeoxycholyl Lysophosphatidylethanolamide Attenuates Hepatofibrogenesis By Impairment Of Tgf-Beta 1/Smad2/3 Signalling

Abstract P-170

A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut–liver axis

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

Fluorofenidone is an Effective Drug for Cholestasis and Fibrosis in a Preclinical Study

Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease

FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output

Oleanolic acid attenuates obstructive cholestasis in bile duct-ligated mice, possibly via activation of NRF2-MRPs and FXR antagonism

The (pro)renin receptor antagonist, PRO20, attenuates high fat diet induced hepatic steatosis and fibrosis in non‐alcoholic fatty liver disease (NAFLD)

Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist

Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents